Analysts expect Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) to post sales of $5.89 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Ascendis Pharma A/S’s earnings, with the lowest sales estimate coming in at $4.39 million and the highest estimate coming in at $6.97 million. Ascendis Pharma A/S posted sales of $900,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 554.4%. The business is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year sales of $49.04 million for the current year, with estimates ranging from $38.10 million to $65.34 million. For the next fiscal year, analysts forecast that the business will report sales of $187.94 million, with estimates ranging from $70.66 million to $297.41 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) last posted its quarterly earnings data on Wednesday, March 2nd. The biotechnology company reported ($2.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.57) by $0.43. The business had revenue of $5.60 million during the quarter, compared to analysts’ expectations of $2.78 million. Ascendis Pharma A/S had a negative net margin of 5,015.63% and a negative return on equity of 45.19%.
Institutional investors have recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $31,000. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Ascendis Pharma A/S by 51.2% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 195 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 66 shares during the last quarter. CI Investments Inc. purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $37,000. Barclays PLC increased its position in shares of Ascendis Pharma A/S by 117.5% during the 4th quarter. Barclays PLC now owns 627 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 4,218 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of Ascendis Pharma A/S by 22.0% during the 3rd quarter. US Bancorp DE now owns 919 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 166 shares during the last quarter.
Shares of NASDAQ ASND opened at $108.29 on Tuesday. The company has a market cap of $6.17 billion, a price-to-earnings ratio of -13.06 and a beta of 0.72. Ascendis Pharma A/S has a 12 month low of $96.97 and a 12 month high of $178.71. The stock has a 50-day moving average price of $111.60 and a two-hundred day moving average price of $128.53.
Ascendis Pharma A/S Company Profile (Get Rating)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
- Get a free copy of the StockNews.com research report on Ascendis Pharma A/S (ASND)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.